Intranasal trivalent live attenuated influenza vaccine for prevention of disease caused by influenza A and B viruses
Record ID 32008000021
English
Authors' objectives:
Live attenuated influenza virus vaccine (LAIV), administered by nasal spray or drops, is an alternative vaccine technology to inactivated influenza virus vaccines, which are generally administered by intramuscular injection. Trivalent, cold-adapted LAIV formulations (CAIV-T), sometimes referred to only as LAIV, are administered annually via intranasal spray in healthy children and adults, to prevent infection with influenza viruses A/H3N2, A/H1N1, and B.
Authors' methods:
Review
Details
Project Status:
Completed
URL for project:
http://www.hayesinc.com/
Year Published:
2007
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Orthomyxoviridae Infections
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
HAYES, Inc.
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.